Mesoblast (ASX:MSB) reported $13.2 million in unaudited gross revenue from sales of its Ryoncil mesenchymal stromal cell product in the June quarter after its launch on March 28, according to a Friday Australian bourse filing.
The firm earlier secured the US Food and Drug Administration's approval for Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in children.
The firm said it has onboarded over 25 transplant centers since the launch of Ryoncil, and it expects to complete the onboarding process across all 45 priority transplant centers in the September quarter.
The drugmaker also reported $1.6 million in revenue from royalties on the sales of Temcell HS Inj. sold in Japan by its licensee.
Mesoblast's shares soared 25% in early trading on Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。